Antimalarial agent 39 (compound 1) is an intermediate in the synthesis of antimalarial agents[1].

Antimicrobial agent-28 (Compound Bicycle molecule) is an antibacterial agent with good affinity for the penicillin-binding protein (PBP3) of Escherichia coli, which can inhibit the activity of Escherichia coli[1].

Antimicrobial agent-29 (Compound C35) affects the interaction between human hemoglobin and Staphylococcus aureus IsdB hemophore. Antimicrobial agent-29 helps the discovery of IsdB:Hb PPI inhibitors[1].

Antioxidant 1010 (lrganox 1010; AT1010) exhibits antioxidant efficacy in plastic, rubber and synthetic fiber[1].

Antioxidant 1010 (lrganox 1010; AT1010) exhibits antioxidant efficacy in plastic, rubber and synthetic fiber[1].

Antioxidant 1010 (lrganox 1010; AT1010) exhibits antioxidant efficacy in plastic, rubber and synthetic fiber[1].

Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells[1].

Antiproliferative agent-49 (Compound 5a) is a EGFR-TK inhibitor with an IC50 of 0.09 μM. Antiproliferative agent-49 is a anti-proliferative agent. Antiproliferative agent-49 displays good activities against HER3 and HER4 with IC50 values 0.18 and 0.37 µM. Antiproliferative agent-49 induces mitochondrial apoptotic pathway and increased accumulation of ROS[1].

Antitubercular agent-45 (Compound 5g) is an antifungal and antitubercular agent. Antitubercular agent-45 inhibits S. aureus, MRSA, B. subtilis, E. coli, C. albicans with MIC values of 6.4, 10.8, 6.1, 8.4 , 8.1 μM respectively[1].

Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active[1].

Antitumor agent-138 (compound 5b) is an inhibitor against tubulin polymerization at tubulin colchicine-binding sites, with IC50 of 1.87 μM. Antitumor agent-138 arrests the cell cycle at G2/M phase and induces an apoptosis in MCF-7 cells. Antitumor agent-138 inhibits cells migration and angiogenesis[1].

Antitumor agent-139 (compound 9b) is a liver – and mitochondria-targeting gold(I) complexe, and produces reactive oxygen species (ROS) and facilitates DNA excretion. Antitumor agent-139 inhibits tumor growth in a patient-derived xenograft model of hepatocellular carcinoma[1].

Antitumor agent-143 (compound 2c) is an antitumor agent that blocks cell proliferation of A549 cells during the S phase and induces an early apoptosis. Antitumor agent-143 induces cell death via ferroptosis, apoptosis by a ROS-mediated mitochondrial dysfunction pathway and GSDMD-mediated pyroptosis[1].

Antitumor agent-144 (16) is an antitumor agent, with IC50 values of 2.6 μM and 8.4 μM in L1210 and KB cells, respectively[1].

Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response[1].

Antitumor agent-149 (Compound 3) is an analogue of Echinomycin (HY-106101). Antitumor agent-149 inhibits HIF-1α-mediated transcription. Antitumor agent-149 induces cancer cell apoptosis. Antitumor agent-149 inhibits tumor growth in SW620 xenograft mice model[1].

Antitumor agent-150 (V10), an anti-breast cancer agent, is a PROTAC-based MDM2 protein degrader (Red: Ganoderic acid A; Black: 4O-PEG linker; Blue: VHL ligand)[1].

Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis[1].

Antitumor agent-152 (Compound 5) is an anticancer agent that can inhibit the uptake of 3H-dC in L1210 leukemia cells with an IC50 value of 1.12 μM[1].

Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity.[12][1].

Antiviral agent 49 (compound 4q) is dual antiviral and antibacterial agent. Antiviral agent 49 shows anti-enterococcus activity and anti-staphylococcal activity[1].

Antiviral agent 51 (compound a) is a potent antiviral agent. Antiviral agent 51 is a fucoidan. Antiviral agent 51 interacts with DENV-2 RNA Dependant RNA polymerase (RdRp)[1].

Antiviral agent 52 (Compound 30) is a Chlorcyclizine (HY-112067) derivative that exhibits antiviral activity against hepatitic C virus (HCV) with an EC50 of 17 nM. Antiviral agent 52 reveals cytotoxicity in cell Huh7.5.1 with CC50 of 21.3 μM[1].

Antiviral agent 53 (Compound (S)-4v) is an antiviral agent that can inhibit the activity of Potato virus Y (PVY) and exhibit excellent curative and protective effects against PVY with EC50 values of 328.6 and 256.1 μg/mL, respectively. Antiviral agent 53 can be used in the research and development of novel pesticides[1].

Antiviral agent 54 (compound 33) is a broad-spectrum and orally active antiviral agent. Antiviral agent 54 shows antiviral activity for ZIKV, HCoV-OC43 and influenza A virus (IVA). Antiviral agent 54 decreases the ZIKV RNA and protein level[1].

ANTXR1 Human Pre-designed siRNA Set A contains three designed siRNAs for ANTXR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANTXR2 Human Pre-designed siRNA Set A contains three designed siRNAs for ANTXR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA1 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA10 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA11 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA13 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA2 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA2R Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA2R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA3 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA4 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA5 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA6 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA7 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA8 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ANXA9 Human Pre-designed siRNA Set A contains three designed siRNAs for ANXA9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOAH Human Pre-designed siRNA Set A contains three designed siRNAs for AOAH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOC1 Human Pre-designed siRNA Set A contains three designed siRNAs for AOC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOC2 Human Pre-designed siRNA Set A contains three designed siRNAs for AOC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for AOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOPEP Human Pre-designed siRNA Set A contains three designed siRNAs for AOPEP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOX1 Human Pre-designed siRNA Set A contains three designed siRNAs for AOX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AOZ/BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of AOZ (HY-W012982) and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

AOZ/OVA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of AOZ () and OVA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].